Continue to learn
On July 13, 2024, Maxvax’s recombinant herpes zoster (Shingles) vaccine (CHO cell) finished the enrollment of its first human subject for Phase III clinical trial in China’s Henan Province, marking the launch of the vaccine’s Phase III clinical trial.
more >On April 12, 2024, Chengdu Maxvax Biotechnology LLC. (hereinafter referred to as “Maxvax”) announced the IND application for its recombinant protein respiratory syncytial virus (RSV) vaccine (CHO cell) has been officially accepted by the Center for Drug Evaluation (CDE) of China’s State Drug Administration （Acceptance No.: CXSL2400228）.
more >Chengdu Maxvax Biotechnology LLC. recently announced the completion of its Series C+ financing round, raising over 300 million CNY.
more >Recently, Chengdu Maxvax Biotechnology LLC. (hereinafter referred to as "Maxvax") announced the completion of its Series C financing round, raising nearly 300 million CNY.
more >On June 28, 2024, Chengdu Maxvax Biotechnology LLC (hereinafter referred to as “Maxvax”) announced that its application for a clinical trial of a new vaccine - recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) - has been approved by China’s Center for Drug Evaluation (CDE).
more >Maxvax has received funding from the Bill & Melinda Gates Foundation to support the development of a low-cost HPV therapeutic vaccine candidate, aligning with global efforts to address the challenges posed by HPV infection that can lead to cervical cancer.
more >
On July 13, 2024, Maxvax’s recombinant herpes zoster (Shingles) vaccine (CHO cell) finished the enrollment of its first human subject for Phase III clinical trial in China’s Henan Province, marking the launch of the vaccine’s Phase III clinical trial.
more >
Chengdu Maxvax Biotechnology LLC. recently announced the completion of its Series C+ financing round, raising over 300 million CNY.
more >
On June 28, 2024, Chengdu Maxvax Biotechnology LLC (hereinafter referred to as “Maxvax”) announced that its application for a clinical trial of a new vaccine - recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) - has been approved by China’s Center for Drug Evaluation (CDE).
more >
On April 12, 2024, Chengdu Maxvax Biotechnology LLC. (hereinafter referred to as “Maxvax”) announced the IND application for its recombinant protein respiratory syncytial virus (RSV) vaccine (CHO cell) has been officially accepted by the Center for Drug Evaluation (CDE) of China’s State Drug Administration （Acceptance No.: CXSL2400228）.
more >
Recently, Chengdu Maxvax Biotechnology LLC. (hereinafter referred to as "Maxvax") announced the completion of its Series C financing round, raising nearly 300 million CNY.
more >
Maxvax has received funding from the Bill & Melinda Gates Foundation to support the development of a low-cost HPV therapeutic vaccine candidate, aligning with global efforts to address the challenges posed by HPV infection that can lead to cervical cancer.
more >